Lilly, Amgen and more back advocacy group's push to double migraine research dollars

When it comes to neurologic diseases, migraine gets only about half the funding that others get. But a new campaign looks to challenge that reality with the fundraising push "Research is Hope."

The effort comes from advocacy group Association of Migraine Disorders (AMD)—which is backed by most of the major migraine pharma players, including Eli Lilly, Allergan, Amgen, Novartis, Teva and Biohaven—and it doubles down on research with the promise to match every dollar donated up to $100,000.